Antitubulin Agents: Colchicine, Vinca Alkaloids, and Podophyllin

Snow, Jerry W.; Kao, Louise; Furbee, R. Brent

doi:10.1007/978-3-319-17900-1_138

Cited by 1 publication

(1 citation statement)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vinblastine and vincristine are close chemical derivatives of each other differing in only one group (methyl for the former and aldehyde for the latter) 69 . Vinca alkaloids inhibit cellular proliferation by binding to tubulin and hindering the activities of the mitotic spindle in lower concentrations, though in higher concentrations, the entire microtubule can be destabilized 70 . As is typically seem in anti-cancer chemotherapies, they are metabolized by CYP3A4 and CYP3A5 with the former being generally more critical for vinblastine and the latter for vincristine 71 , 72 .…”

Section: Cytoskeleton-targetingmentioning

confidence: 99%

Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer

Jiang

Cai

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Non-small cell lung cancer is recognized as the deadliest cancer across the globe. In some areas, it is more common in women than even breast and cervical cancer. Its rise, vaulted by smoking habits and increasing air pollution, has garnered much attention and resource in the medical field. The first lung cancer treatments were developed more than half a century ago. Unfortunately, many of the earlier chemotherapies often did more harm than good, especially when they were used to treat genetically unsuitable patients. With the introduction of personalized medicine, physicians are increasingly aware of when, how, and in whom, to use certain anti-cancer agents. Drugs such as tyrosine kinase inhibitors, anaplastic lymphoma kinase inhibitors, and monoclonal antibodies possess limited utility because they target specific oncogenic mutations, but other drugs that target mechanisms universal to all cancers do not. In this review, we discuss many of these non-oncogene-targeting anti-cancer agents including DNA replication inhibitors ( i . e ., alkylating agents and topoisomerase inhibitors) and cytoskeletal function inhibitors to highlight their application in the setting of personalized medicine as well as their limitations and resistance factors.

show abstract